AMH Equity Ltd Boosts Stock Position in CollPlant Biotechnologies Ltd. (NASDAQ:CLGN)

AMH Equity Ltd grew its stake in CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) by 17.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 116,500 shares of the company’s stock after purchasing an additional 17,295 shares during the period. AMH Equity Ltd owned approximately 1.02% of CollPlant Biotechnologies worth $419,000 at the end of the most recent reporting period.

Separately, Benjamin Edwards Inc. acquired a new position in CollPlant Biotechnologies in the 3rd quarter valued at $112,000. Institutional investors own 21.69% of the company’s stock.

CollPlant Biotechnologies Price Performance

Shares of CLGN stock opened at $3.51 on Thursday. CollPlant Biotechnologies Ltd. has a 1-year low of $3.20 and a 1-year high of $6.75. The business’s fifty day moving average price is $3.77 and its 200 day moving average price is $4.22. The firm has a market capitalization of $40.21 million, a PE ratio of -2.28 and a beta of 0.86.

CollPlant Biotechnologies (NASDAQ:CLGN) last announced its quarterly earnings results on Wednesday, November 27th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). CollPlant Biotechnologies had a negative net margin of 2,680.00% and a negative return on equity of 77.05%. During the same quarter in the previous year, the company posted ($0.38) earnings per share. Equities research analysts expect that CollPlant Biotechnologies Ltd. will post -1.44 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently commented on CLGN shares. D. Boral Capital restated a “buy” rating and issued a $14.00 target price on shares of CollPlant Biotechnologies in a research note on Wednesday, February 12th. HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of CollPlant Biotechnologies in a research report on Friday, November 29th.

CollPlant Biotechnologies Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.